Helius Medical Technologies (NASDAQ:HSDT) Trading Up 4.8% – Still a Buy?

Helius Medical Technologies, Inc. (NASDAQ:HSDTGet Free Report)’s share price was up 4.8% during trading on Monday . The company traded as high as $0.75 and last traded at $0.68. Approximately 913,740 shares were traded during trading, an increase of 222% from the average daily volume of 283,716 shares. The stock had previously closed at $0.65.

Analyst Upgrades and Downgrades

Separately, Maxim Group restated a “hold” rating on shares of Helius Medical Technologies in a research report on Wednesday, October 16th.

View Our Latest Research Report on HSDT

Helius Medical Technologies Price Performance

The firm has a fifty day moving average price of $0.61 and a two-hundred day moving average price of $0.68. The stock has a market capitalization of $2.54 million, a PE ratio of -0.11 and a beta of 1.47.

Institutional Trading of Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Armistice Capital LLC purchased a new position in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDTFree Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies at the end of the most recent quarter. 18.63% of the stock is currently owned by institutional investors and hedge funds.

About Helius Medical Technologies

(Get Free Report)

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.

See Also

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.